These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37549545)

  • 1. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs.
    Tsui JI; Whitney BM; Korthuis PT; Chan B; Pho MT; Jenkins WD; Young AM; Cooper HLF; Friedmann PD; Stopka TJ; de Gijsel D; Miller WC; Go VF; Westergaard R; Brown R; Seal DW; Zule WA; Feinberg J; Smith GS; Mixson LS; Fredericksen R; Crane HM; Delaney JA;
    Drug Alcohol Depend; 2023 Sep; 250():110911. PubMed ID: 37549545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
    Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
    Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
    Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.
    Corry B; Underwood N; Cremer LJ; Rooks-Peck CR; Jones C
    Drug Alcohol Depend; 2022 Jul; 236():109495. PubMed ID: 35605533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
    Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
    Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample.
    Krawczyk N; Garrett B; Ahmad NJ; Patel E; Solomon K; Stuart EA; Saloner B
    Drug Alcohol Depend; 2021 Mar; 220():108512. PubMed ID: 33508692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
    Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
    Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.
    Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Edwards RR; Samet JH
    Drug Alcohol Depend; 2016 Sep; 166():26-31. PubMed ID: 27422763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
    Mintz CM; Presnall NJ; Xu KY; Hartz SM; Sahrmann JM; Bierut LJ; Grucza RA
    Drug Alcohol Depend; 2021 Sep; 226():108886. PubMed ID: 34245997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
    Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
    Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.